Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
tagraxofusp adp-ribosylation factor-like protein 2 biotech NA drugbank Plasmacytoid Dendritic Cells[MeSHID:D003713]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Biological Markers[MeSHID:D015415]
Intention - mental process[MeSHID:D033182]
Lymph[MeSHID:D008196]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Leukemia
Myelocytic
Acute[MeSHID:D015470]		 NA approved,investigational binder
tagraxofusp interleukin 3 receptor alpha NA Successful target TTD , DGIDB Plasmacytoid Dendritic Cells[MeSHID:D003713]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Biological Markers[MeSHID:D015415]
Intention - mental process[MeSHID:D033182]
Lymph[MeSHID:D008196]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Leukemia
Myelocytic
Acute[MeSHID:D015470]		 6.37 approved unknown
tagraxofusp interleukin-3 receptor subunit alpha biotech NA drugbank , DGIDB Plasmacytoid Dendritic Cells[MeSHID:D003713]
Neoplasms[MeSHID:D009369]
Cells[MeSHID:D002477]
Hematologic Neoplasms[MeSHID:D019337]
Biological Markers[MeSHID:D015415]
Intention - mental process[MeSHID:D033182]
Lymph[MeSHID:D008196]
Continuance of life[MeSHID:D013534]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Leukemia
Myelocytic
Acute[MeSHID:D015470]		 6.37 approved,investigational binder
click here to return to the previous page